COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04606563

James A Russell

Not reported

2020-10-28

Terminated

RCT

Randomized

Parallel

Open label

multi-center

Treatment

inclusion criteria: hospitalized must be first admission of covid-19, not re-admission primary reason for hospitalization or prolonged hospitalization is because of acute covid-19 diagnosis adults 18 years of age or greater laboratory-proven covid-19 within 14 days prior to hospital admission

hypotension (sap < 100 mmhg or dap < 50 mmhg or map < 65 mmhg) hyperkalemia (> 5.5 mmol/l) acute kidney injury (urine output < 0.5 ml/kg/hr and new creatinine > 200 mmol/l, or increase > 100 mmol/l, or gfr < 30 ml/min) use of aliskiren in patients with diabetes mellitus (type 1 or type 2) or moderate-severe renal impairment (gfr less than 60ml/min) use of arb/acei within 7 days of presentation pregnant or breastfeeding have a known allergy to arbs or any component of the drug product have written legal document to withhold life-sustaining (patients not wishing to receive cardiopulmonary resuscitation (cpr) can participate if other medical treatments will be given) have signed a do no resuscitate (dnr) form

2

University of British Columbia

18

100

Canada;France

Moderate/severe/critical disease at enrollment

5: Moderate/severe/critical disease at enrollment

341

Mortality

None

Phase 3

[{"arm_notes": "", "treatment_id": 86, "treatment_name": "Angiotensin receptor blocker (arb)", "treatment_type": "Cardiovascular agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]